Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

BACKGROUND: Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new oral antivirals from December 2013 to June 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurain, Anne, Metivier, Sophie, Haour, Georges, Larrey, Dominique, Dorival, Céline, Hezode, Christophe, Zoulim, Fabien, Marcellin, Patrick, Bourliere, Marc, Zarski, Jean-Pierre, Thabut, Dominique, Alric, Laurent, Ganne-Carrie, Nathalie, Cales, Paul, Bronowicki, Jean-Pierre, Riachi, Ghassan, Geist, Claire, Causse, Xavier, Abergel, Armand, Chazouilleres, Olivier, Mathurin, Philippe, Guyader, Dominique, Samuel, Didier, Tran, Albert, Loustaud-Ratti, Véronique, Petrov-Sanchez, Ventzislava, Diallo, Alpha, Luzivika-Nzinga, Clovis, Fontaine, Hélène, Carrat, Fabrice, Pol, Stanislas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446259/
https://www.ncbi.nlm.nih.gov/pubmed/30940090
http://dx.doi.org/10.1186/s12879-019-3923-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446259/
https://www.ncbi.nlm.nih.gov/pubmed/30940090
http://dx.doi.org/10.1186/s12879-019-3923-5

Ejemplares similares